The Pharma Data

DECEMBER 13, 2020

HMBD-001 is a uniquely differentiated anti-HER3 neutralizing antibody that was developed using Hummingbird’s proprietary Rational Antibody Discovery platform. HMBD-001 has been immune-engineered to bind with high affinity to the HER3 dimerization interface and block HER3 growth signals to the cancer. ” About NRG1 fusions.

Clinical Development 40

Clinical Development Medicine Development Antibody 40

pharmaphorum

OCTOBER 13, 2022

Bayer’s quest to revamp its drug discovery engine continues apace, with the company’s recently acquired Vividion subsidiary forging an alliance with Tavros Therapeutics, aimed at finding new drug targets and biomarkers in oncology. million in future payments tied to preclinical, clinical development, and commercial achievements.

Gene Therapy 64

Gene Therapy Genome Genomics Drugs 64

XTalks

OCTOBER 20, 2023

Clinical-stage genome editing company Intellia Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to start a pivotal phase III trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy.

In-Vivo 52

In-Vivo Gene Editing Trials Gene 52

XTalks

SEPTEMBER 21, 2023

XTALKS WEBINAR: Clinical Trial Risk Identification, Management and Reporting from Clinical Development to Marketing Live and On-Demand: Friday, October 27, 2023, at 10am EDT (4pm CEST/EU-Central) Register for this free webinar to learn how to successfully develop and maintain the safety profile of medicinal products.

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

The Pharma Data

NOVEMBER 9, 2020

Currently in late-phase clinical development, NVXCoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes its proprietary MatrixM adjuvant. NVX-CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

The Pharma Data

JANUARY 13, 2021

HPN217, a tri-specific T cell activating recombinant protein construct (TriTAC®) targets B-cell maturation antigen (BCMA), a well-validated antigen expressed on malignant multiple myeloma cells. Food and Drug Administration (FDA) has granted Orphan Drug Designation for HPN217 for the treatment of multiple myeloma.

Drugs 52

Drugs Clinical Trials Clinical Trials Containment 52

The Pharma Data

DECEMBER 8, 2020

Now poised to advance a robust therapeutics pipeline to clinical development, Nuance will use the funds for ongoing R&D of existing products and business development of potential new assets. Through its Shielded Living Therapeutics platform, the company is developing functional cures for chronic diseases.

RNA 52

RNA Antibody Life Science Protein 52

XTalks

FEBRUARY 24, 2023

Lunsumio is a CD20xCD3 T-cell engaging bispecific antibody that works by targeting the protein CD20 on the surface of B cells and CD3 on the surface of T cells. Laport: Building on a legacy of more than 20 years of innovation in blood cancer, I am proud that Lunsumio was developed and discovered by our own Genentech scientists.

Drugs 52

Drugs FDA Approval Antibody Medicine 52

The Pharma Data

OCTOBER 27, 2020

Sirnaomics is the only biopharma conducting R&D and clinical development in the field of RNAi therapeutics in both the U.S. Be Bio is a leader in developing B cells as medicines. Be Bio plans to use their $52 million Series A to precisely engineer B cells to treat a range of diseases. Be Biopharma .

Gene 52

Gene Gene Therapy Medicine Development 52

The Pharma Data

DECEMBER 10, 2020

The vaccine targeted both the inner nucleocapsid (N) and the outer spike (S) proteins of the virus to maximize the immune response. ImmunityBio’s platform is based on the foundation of three separate modalities: antibody cytokine fusion proteins, synthetic immunomodulators, and second-generation human adenovirus (hAd5) vaccine technologies.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

The Pharma Data

NOVEMBER 10, 2020

Growing into a biopharmaceutical company, Innovent has built an integrated platform covering from drug discovery, CMC, clinical development and commercialization. that are fast progressing clinical trials. Michael Yu reviewed the history and achievements in the past nine years since the establishment of Innovent.

Clinical Trials 52

Clinical Trials Clinical Trials Production Manufacturing 52

The Pharma Data

OCTOBER 26, 2020

AR-711 exhibits high affinity for SARS-CoV-2 spike protein, approximately 10-fold or higher than mAb candidates currently in late stage clinical testing. AR-301 is a fully human IgG1 mAb currently in Phase 3 clinical development targeting gram-positive Staphylococcus aureus ( S. AR-301 (VAP). AR-101 (HAP).

Antibody 52

Antibody Genetic Engineering Development Clinical Trials 52

The Pharma Data

JUNE 2, 2022

Immatics will be responsible for preclinical development of the initial two Bristol Myers Squibb-owned programs and will receive additional payment for certain activities that Immatics could perform at Bristol Myers Squibb’s request. This enables the redirection of gamma delta T cells to cancer cell targets.

Development 52

Development Manufacturing Sales Production 52

The Pharma Data

JUNE 1, 2022

Under her leadership, Pfizer advanced into clinical development or approval bacterial vaccine programs directed at the prevention of diseases due to Streptococcus pneumoniae, Group B Streptococcus, Neisseria meningitidis, Staphylococcus aureus, and Clostridium difficile. Dr. Anderson joined Pfizer via Wyeth in 2007.

Vaccination 40

Vaccination Vaccine Development Research 40

The Pharma Data

NOVEMBER 2, 2020

But the protein is cleared from the body too quickly to be useful, explained Arora, who was with biotech company Genentech at the time of the study. So, Arora and his colleagues there developed a lab-engineered antibody that essentially mimics the hormone. More information. SOURCES: Puneet Arora, M.D., 2, 2020, online.

Antibody 52

Antibody Drugs Hormones Insulin 52

Roots Analysis

OCTOBER 30, 2023

These RNA based therapeutics play a crucial role in protein production and regulation of gene functions. The support from venture capitalists and big pharmaceutical companies will continue to drive the development of circular RNA therapeutics and RNA therapeutics market growth over the forecast period.

RNA 40

RNA Vaccination Vaccine Development 40

The Pharma Data

MAY 27, 2022

It is engineered to have two ‘Fab’ regions which bind to CD20, and one ‘Fab’ region which binds to CD3. This dual targeting activates and redirects a patient’s existing T-cells to engage and eliminate target B-cells by releasing cytotoxic proteins into the B-cells. Glofitamab is based on a novel structural format called ‘2:1’.

Antibody 52

Antibody In-Vitro Medicine Engineer 52

The Pharma Data

JUNE 7, 2023

Results will be presented on June 6 during an oral presentation (#9004) at the American Society of Clinical Oncology Annual Meeting (#ASCO23). Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN).

Trials 40

Trials Antibody Development Genome 40

XTalks

MAY 9, 2024

What factors do you attribute to the company’s success in the discovery and development of differentiated antibody therapeutics? With hundreds of antibodies undergoing pre-clinical and clinical development, it is anticipated that the number of antibody medications in clinical trials and approved by regulatory agencies will rise.

Antibody 52

Antibody Clinical Trials Clinical Trials Medicine 52

The Pharma Data

OCTOBER 19, 2020

Caris Precision Oncology Alliance members also have access to the Caris Pharmatech oncology trial network, which can help reduce the time it takes to identify and connect appropriate patients with novel targeted cancer therapies in clinical development.

Life Science 52

Life Science Clinical Trials Clinical Trials RNA 52

The Pharma Data

JUNE 26, 2021

The safety profile of PDS in the clinical trial setting is well understood and will continue to be closely monitored. Roche has a robust phase III clinical development programme underway for PDS, including the Portal, Pagoda and Pavilion studies. 9 Both the Pagoda and Pavilion trials are actively recruiting participants.

Drug Delivery 52

Drug Delivery Clinical Trials Clinical Trials Medicine 52

The Pharma Data

NOVEMBER 4, 2020

Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”). For additional information, please visit [link].

Licensing 40

Licensing Licensing Dermatology Production 40

The Pharma Data

OCTOBER 14, 2020

TNX-1800 is a live modified horsepox virus vaccine for percutaneous administration that is designed to express the Spike protein of the SARS-CoV-2 virus that causes COVID-19 and to elicit a predominant T cell response. Horsepox and vaccinia are closely related orthopoxviruses that are believed to share a common ancestor.

Vaccination 40

Vaccination Vaccine Development Medicine 40

XTalks

FEBRUARY 3, 2021

Biotech company Novavax (Nasdaq: NVAX ) reported that its protein-based vaccine demonstrated an efficacy of 89.3 Novavax’s Protein Vaccine. Of the leading vaccine candidates, Novavax’s shot (NVX-CoV2373) is one of the first protein vaccines in late-stage trials for COVID-19. variant that first popped up in the country.

Vaccination 103

Vaccination Vaccine Trials Protein 103

pharmaphorum

FEBRUARY 25, 2021

Pandion ’s lead candidate PT101 has completed a phase 1a clinical trial backing its safety and tolerability, and is due to start a phase 1a/2b study in ulcerative colitis and a phase 2 trial in systemic lupus erythematosus before the end of the year.

Clinical Trials 71

Clinical Trials Clinical Trials Immune Response Trials 71

The Pharma Data

OCTOBER 27, 2020

Under the agreement, during the option period, Molecular Partners will conduct Phase 1 clinical trials for MP0420, expected to begin in November 2020, and perform all remaining preclinical work for MP0423 and Novartis will conduct Phase 2 and Phase 3 clinical trials, with Molecular Partners as sponsor of these trials.

Development 40

Development Protein Manufacturing Medicine 40

XTalks

SEPTEMBER 19, 2024

It was engineered to have high potency, bioavailability and kinase selectivity that led to improved efficacy and safety in B-cell malignancies. The mechanism of action of our BTK CDAC allows for complete degradation of the BTK protein and has distinct advantages over current BTK inhibitors.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Clinical Research 52

Pharmaceutical Technology

FEBRUARY 24, 2023

ACE-1334 is under clinical development by Merck and currently in Phase I for Lung Disease. ACE-1334 overview ACE-1334 is under development for the treatment of pulmonary disease with fibrotic component and systemic sclerosis and its associated interstitial lung disease. It is developed based on protein engineering platform.

Production 100

Production Vaccination Vaccine Engineer 100

The Pharma Data

NOVEMBER 22, 2020

It was engineered with the intention of improving deep-lung delivery of Treprostinil in PAH patients by means of a dry powder inhaler. Liquidia Technologies has a target action date of November 24 for its NDA for LIQ861 for treatment of pulmonary arterial hypertension (PAH). The drug was approved for that indication on November 13.

Licensing 52

Licensing Licensing Drugs Gene 52

Delveinsight

FEBRUARY 12, 2021

Furthermore, GlaxoSmithKline is developing GSK3377794 (NY-ESO-1 T-cells; GSK ‘794), a NY-ESO-1-directed genetically modified autologous T-cell immunotherapy and is an engineered T-cell therapy. What can be expected from ongoing clinical trials in the Synovial sarcoma landscape? million in 2017.

Marketing 52

Marketing Clinical Trials Clinical Trials Development 52

The Pharma Data

AUGUST 9, 2021

We believe this highly sophisticated and specifically engineered ADC is fulfilling its promise to reshape the treatment of HER2-positive metastatic breast cancer, with the goal to move into earlier lines of treatment for HER2-positive breast cancer and many other HER2-expressing tumour types across our broad clinical trial programme.”.

Trials 52

Trials Medicine Development Clinical Trials 52

The Pharma Data

JANUARY 24, 2021

25, 2021 /PRNewswire/ — Elasmogen Ltd , the pioneering biopharmaceutical company leading the development of VNAR and soloMER biologics, today announces a significant breakthrough in the identification of next-generation protein-based drugs potentially capable of stopping COVID-19 infections. ABERDEEN, Scotland , Jan.

Antibody 40

Antibody Protein Research Genetic Engineering 40

The Pharma Data

JANUARY 13, 2021

TNX-1500 is a third generation anti-CD40-ligand mAb that has been designed by protein engineering to decrease Fc?RII CD40-ligand is a protein expressed on the surface of activated T lymphocytes that mediates T cell helper function. antagonist receptor fusion protein. 175:1091-1101 (1992) 2 Karpusas, M et al.,

Antibody 52

Antibody Development Protein Vaccination 52

The Pharma Data

OCTOBER 26, 2020

Based on these promising findings, Transgene intends to continue the clinical development of TG4001 in a larger, controlled confirmatory study as we look to provide a better treatment option for this patient population,” added Dr. Maud Brandely, MD, PhD, Chief Medical Officer of Transgene. Conclusions.

Vaccination 40

Vaccination Vaccine Trials Containment 40

pharmaphorum

JANUARY 16, 2023

This is linked to wider questions about the role damaged proteins and their build up plays in ageing across different tissues and organs. The fundamental engine of innovation for the global pharmaceutical industry continues.

Gene Therapy 98

Gene Therapy In-Vitro Gene Medicine 98

The Pharma Data

SEPTEMBER 15, 2020

With the depth and breadth of our current portfolio, the tremendous potential of our pipeline and scientific engine, and the power of our culture of innovation, we are poised to continue delivering meaningful value to patients by addressing some of the world’s most difficult health challenges.”.

Gene Therapy 52

Gene Therapy Vaccination Vaccine Trials 52

The Pharma Data

MARCH 26, 2021

Preclinical data suggest VIR-7831 targets a highly conserved epitope of the spike protein, which may make it more difficult for resistance to develop. About the VIR-7831 Clinical Development Programme. About the Vir and GSK Collaboration. An earlier stage collaboration with SK Bioscience is also ongoing.

Antibody 52

Antibody Trials Vaccination Vaccine 52